Pooja Patel, MD
Allergy & Immunology · Merrillville, INNPI 1841585692
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,975 of the $55,473 with a category attached, or 88.3%. GSK accounts for 81.9% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $46,322 and has fallen 98.5% since, to $686 in 2025.
Across 184 payments — averaging $301.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$45K
- AstraZeneca$7K
- Sanofi$660
- Bard Peripheral Vascular, Inc.$270
- Alk-abello, Inc$246
- Grifols USA, LLC$180
- plus $2K from 25 others
Across 2 payments — averaging $15,608 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$31K
What the payments were for
- Speaking & faculty fees$48,97588%
- Grants$5001%
- Travel & lodging$7491%
- Food & beverage$5,2159%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 65 | $45,458 |
| AstraZeneca | 46 | $6,884 |
| Sanofi | 7 | $660 |
| Bard Peripheral Vascular, Inc. | 2 | $270 |
| Alk-abello, Inc | 6 | $246 |
| Grifols USA, LLC | 8 | $180 |
| Lilly USA, LLC | 3 | $157 |
| Boehringer Ingelheim | 2 | $145 |
| Genentech USA, Inc. | 2 | $145 |
| Boston Scientific | 1 | $142 |
| Cook Medical LLC | 1 | $137 |
| Harrow Eye, LLC | 1 | $132 |
| Inari Medical, Inc. | 1 | $122 |
| Novartis | 6 | $106 |
| Amgen(2 entities) | 5 | $101 |
| Kaleo, Inc. | 3 | $75 |
| Covis Pharma GmbH | 4 | $64 |
| Blueprint Medicines Corporation | 1 | $62 |
| Greer Laboratories, Inc. | 2 | $44 |
| Octapharma USA, Inc. | 2 | $43 |
| Revance Therapeutics, Inc. | 1 | $43 |
| Aimmune Therapeutics, Inc. | 3 | $42 |
| Hikma Pharmaceuticals USA | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $30 |
| Lundbeck LLC | 2 | $29 |
| AbbVie | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| USWM, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$38,894
- TEZSPIRE$5,865
- JARDIANCE$250
- FLOWTRIEVER CATHETER, S$244
- Lutonix Drug Coated Balloon$152
- WATCHMAN Access System$142
- Zilver Vena$137
- XOLAIR$129
- AIRSUPRA$125
- Fluency Endovascular Stent Graft$118
- TRELEGY ELLIPTA$117
- NUCALA$102
How this compares
$55,473 in reported general payments places this provider in the 85th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 14 | $52,389 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $48,218 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $21,284 |
| Epinephrine | 49 | $5,667 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $5,094 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $4,569 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,807 |
| Fluticasone Propionate | 111 | $1,701 |
| Azelastine Hcl | 54 | $1,215 |
| Levocetirizine Dihydrochloride | 95 | $1,090 |
| Montelukast Sodium | 72 | $775 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $774 |
| Olopatadine Hcl | 15 | $769 |
| Ipratropium Bromide | 21 | $669 |
| Mometasone Furoate | 23 | $545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $45,458 | $69,50282 claims |
| Hikma Pharmaceuticals USAEpinephrine | $40 | $5,66749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Merrillville
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Majed KoleilatEvansville$122K
- Pinkus GoldbergIndianapolis$89K
- Douglas NeeldFort Wayne$77K
- Mitchell SmithGreenwood$33K
- Ketan ShethLafayette$30K
- Jennifer RumpelPortage$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.